Cargando…

Fisetin as an adjuvant treatment in prostate cancer patients receiving androgen-deprivation therapy

Detalles Bibliográficos
Autores principales:	Lorenzo, Giuseppe Di, Scafuri, Luca, Costabile, Ferdinando, Pepe, Liuba, Scognamiglio, Anna, Crocetto, Felice, Guerra, Germano, Buonerba, Carlo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Future Science Ltd 2022
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8890115/ https://www.ncbi.nlm.nih.gov/pubmed/35251698 http://dx.doi.org/10.2144/fsoa-2022-0002

Ejemplares similares

Kaempferol, Myricetin and Fisetin in Prostate and Bladder Cancer: A Systematic Review of the Literature
por: Crocetto, Felice, et al.
Publicado: (2021)

Does perioperative systemic therapy represent the optimal therapeutic paradigm in organ-confined, muscle-invasive urothelial carcinoma?
por: Scafuri, Luca, et al.
Publicado: (2021)

COVID-19 and prostate cancer: a complex scenario with multiple facets
por: Crocetto, Felice, et al.
Publicado: (2021)

Adjuvant androgen deprivation therapy for prostate cancer treated with radiation therapy
por: Siddiqui, Zaid A., et al.
Publicado: (2018)

Outcomes Associated with First-Line anti-PD-1/ PD-L1 agents vs. Sunitinib in Patients with Sarcomatoid Renal Cell Carcinoma: A Systematic Review and Meta-Analysis
por: Buonerba, Carlo, et al.
Publicado: (2020)

Immune checkpoint inhibitors in penile cancer
por: Buonerba, Carlo, et al.
Publicado: (2021)

The androgen-thyroid hormone crosstalk in prostate cancer and the clinical implications
por: Torabinejad, Sepehr, et al.
Publicado: (2023)

A pilot study of exercise in men with prostate cancer receiving androgen deprivation therapy
por: Lee, C Ellen, et al.
Publicado: (2012)

Decreased Risk of Renal Calculi in Patients Receiving Androgen Deprivation Therapy for Prostate Cancer
por: Lin, Chien-Yu, et al.
Publicado: (2020)

Risk of ischemic stroke in patients with prostate cancer receiving androgen deprivation therapy in Taiwan
por: Liao, Kuang-Ming, et al.
Publicado: (2019)

Risk of esophageal and gastric adenocarcinoma in men receiving androgen deprivation therapy for prostate cancer
por: Shore, Richard, et al.
Publicado: (2021)

Androgen deprivation and cognition in prostate cancer
por: Salminen, E, et al.
Publicado: (2003)

Adjuvant androgen deprivation impacts late rectal toxicity after conformal radiotherapy of prostate carcinoma
por: Sanguineti, G, et al.
Publicado: (2002)

Impact of Adjuvant Androgen-Deprivation Therapy on Disease Progression in Patients with Node-Positive Prostate Cancer
por: Park, Sejun, et al.
Publicado: (2011)

Predictors of Outcomes in Patients with EGFR-Mutated Non-Small Cell Lung Cancer Receiving EGFR Tyrosine Kinase Inhibitors: A Systematic Review and Meta-Analysis
por: Buonerba, Carlo, et al.
Publicado: (2019)

Patients receiving androgen deprivation therapy for prostate cancer have an increased risk of depressive disorder
por: Chung, Shiu-Dong, et al.
Publicado: (2017)

Clinical factors affecting prostate-specific antigen levels in prostate cancer patients undergoing radical prostatectomy: a retrospective study
por: Tarantino, Giovanni, et al.
Publicado: (2021)

Prostate cancer, insulin, and androgen deprivation therapy
por: Stattin, P, et al.
Publicado: (2003)

The effect of continuous androgen deprivation treatment on prostate cancer patients as compared with intermittent androgen deprivation treatment
por: Ku, Ja Yoon, et al.
Publicado: (2015)

Contralateral prophylactic mastectomy in male breast cancer: where do we stand?
por: Sciarra, Antonella, et al.
Publicado: (2021)

Platelet to lymphocyte ratio as an independent prognostic indicator for prostate cancer patients receiving androgen deprivation therapy
por: Wang, Yanqing, et al.
Publicado: (2016)

Prognostic significance of diabetes mellitus and dyslipidemia in men receiving androgen-deprivation therapy for metastatic prostate cancer
por: Hirata, Yu, et al.
Publicado: (2019)

Favorable prognosis of patients who received adjuvant androgen deprivation therapy after radiotherapy achieving undetectable levels of prostate-specific antigen in high- or very high-risk prostate cancer
por: Jeong, Jae-Uk, et al.
Publicado: (2021)

Androgen receptor splice variant 7 detected by immunohistochemical is an independent poor prognostic marker in men receiving adjuvant androgen-deprivation therapy after radical prostatectomy
por: Ouyang, Wei, et al.
Publicado: (2021)

Combined brachytherapy and external beam radiotherapy without adjuvant androgen deprivation therapy for high-risk prostate cancer
por: Ohashi, Toshio, et al.
Publicado: (2014)

Improving survival in salivary duct cancer with adjuvant androgen deprivation therapy
por: van Boxtel, Wim, et al.
Publicado: (2019)

Hedgehog/Gli supports androgen signaling in androgen deprived and androgen independent prostate cancer cells
por: Chen, Mengqian, et al.
Publicado: (2010)

Duration of androgen deprivation therapy with maximum androgen blockade for localized prostate cancer
por: Fujimoto, Naohiro, et al.
Publicado: (2011)

Prostate-Specific Antigen Kinetics Effects on Outcomes of Low-Volume Metastatic Prostate Cancer Patients Receiving Androgen Deprivation Therapy
por: Lin, Yen-Chi, et al.
Publicado: (2021)

Reply: Prostate cancer, insulin and androgen deprivation therapy
por: Lehrer, S
Publicado: (2003)

Androgen deprivation therapy for prostate cancer and risk of dementia
por: Robinson, David, et al.
Publicado: (2019)

Androgen deprivation therapy in high risk prostate cancer
por: Van Dams, Ritchell, et al.
Publicado: (2019)

Cardiovascular Risks of Androgen Deprivation Therapy for Prostate Cancer
por: Corona, Giovanni, et al.
Publicado: (2021)

Efficacy of walking exercise in promoting cognitive-psychosocial functions in men with prostate cancer receiving androgen deprivation therapy
por: Lee, C Ellen, et al.
Publicado: (2012)

Inherited Variants in Wnt Pathway Genes Influence Outcomes of Prostate Cancer Patients Receiving Androgen Deprivation Therapy
por: Geng, Jiun-Hung, et al.
Publicado: (2016)

Cardiovascular Disease Risk Factors: How Relevant in African Men With Prostate Cancer Receiving Androgen-Deprivation Therapy?
por: Essien, Okon Ekwere, et al.
Publicado: (2016)

Prostate Cancer Incidence under Androgen Deprivation: Nationwide Cohort Study in Trans Women Receiving Hormone Treatment
por: de Nie, Iris, et al.
Publicado: (2020)

Efficacy of Androgen Deprivation Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer Receiving Docetaxel-Based Chemotherapy
por: Min, Kyungchan, et al.
Publicado: (2020)

Physical exercise for bone health in men with prostate cancer receiving androgen deprivation therapy: a systematic review
por: Bressi, Barbara, et al.
Publicado: (2020)

Multidisciplinary Consensus on the Prevention and Treatment of Osteoporosis and Fragility Fractures in Patients with Prostate Cancer Receiving Androgen-Deprivation Therapy
por: Casado, Enrique, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_7c2msk5fi0plbevmhfni10h9sg